SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Angela Wahl, Lisa E. Gralinski, Claire E. Johnson, Wenbo Yao, Martina Kovarova, Kenneth H. Dinnon, Hongwei Liu, Victoria J. Madden, Halina M. Krzystek, Chandrav De, Kristen K. White, Kendra Gully, Alexandra Schäfer, Tanzila Zaman, Sarah R. Leist, Paul O. Grant, Gregory R. Bluemling, Alexander A. Kolykhalov, Michael G. Natchus, Frederic B. AskinGeorge Painter, Edward P. Browne, Corbin D. Jones, Raymond J. Pickles, Ralph S. Baric, J. Victor Garcia

Research output: Contribution to journalArticlepeer-review

Abstract

All coronaviruses known to have recently emerged as human pathogens probably originated in bats1. Here we use a single experimental platform based on immunodeficient mice implanted with human lung tissue (hereafter, human lung-only mice (LoM)) to demonstrate the efficient in vivo replication of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as two endogenous SARS-like bat coronaviruses that show potential for emergence as human pathogens. Virus replication in this model occurs in bona fide human lung tissue and does not require any type of adaptation of the virus or the host. Our results indicate that bats contain endogenous coronaviruses that are capable of direct transmission to humans. Our detailed analysis of in vivo infection with SARS-CoV-2 in human lung tissue from LoM showed a predominant infection of human lung epithelial cells, including type-2 pneumocytes that are present in alveoli and ciliated airway cells. Acute infection with SARS-CoV-2 was highly cytopathic and induced a robust and sustained type-I interferon and inflammatory cytokine and chemokine response. Finally, we evaluated a therapeutic and pre-exposure prophylaxis strategy for SARS-CoV-2 infection. Our results show that therapeutic and prophylactic administration of EIDD-2801—an oral broad-spectrum antiviral agent that is currently in phase II/III clinical trials—markedly inhibited SARS-CoV-2 replication in vivo, and thus has considerable potential for the prevention and treatment of COVID-19.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalNature
Volume591
Issue number7850
DOIs
StatePublished - Mar 18 2021
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801'. Together they form a unique fingerprint.

Cite this